- Home
- FORA vs FBRX Comparison
FORA vs FBRX Comparison
Compare FORA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- FBRX
- Stock Information
- Founded
- FORA 2014
- FBRX N/A
- Country
- FORA United States
- FBRX United States
- Employees
- FORA N/A
- FBRX N/A
- Industry
- FORA Computer Software: Prepackaged Software
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- FBRX Health Care
- Exchange
- FORA Nasdaq
- FBRX Nasdaq
- Market Cap
- FORA 77.6M
- FBRX 76.1M
- IPO Year
- FORA N/A
- FBRX N/A
- Fundamental
- Price
- FORA $2.41
- FBRX $10.98
- Analyst Decision
- FORA Strong Buy
- FBRX Strong Buy
- Analyst Count
- FORA 1
- FBRX 4
- Target Price
- FORA $5.00
- FBRX $77.58
- AVG Volume (30 Days)
- FORA 57.0K
- FBRX 27.5K
- Earning Date
- FORA 03-27-2025
- FBRX 03-17-2025
- Dividend Yield
- FORA N/A
- FBRX N/A
- EPS Growth
- FORA N/A
- FBRX N/A
- EPS
- FORA N/A
- FBRX N/A
- Revenue
- FORA $19,709,723.00
- FBRX N/A
- Revenue This Year
- FORA N/A
- FBRX N/A
- Revenue Next Year
- FORA $13.59
- FBRX N/A
- P/E Ratio
- FORA N/A
- FBRX N/A
- Revenue Growth
- FORA N/A
- FBRX N/A
- 52 Week Low
- FORA $1.96
- FBRX $4.11
- 52 Week High
- FORA $4.15
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- FORA 48.34
- FBRX 36.53
- Support Level
- FORA $2.35
- FBRX $9.81
- Resistance Level
- FORA $4.03
- FBRX $13.13
- Average True Range (ATR)
- FORA 0.45
- FBRX 1.52
- MACD
- FORA -0.01
- FBRX -0.08
- Stochastic Oscillator
- FORA 19.00
- FBRX 18.17
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).